Interferon Beta-1B Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Multiple Sclerosis

Initial dose: 0.0625 mg subcutaneously every other day, and increased (in 25% increments) every 2 weeks, over a 6 week period, to maintenance dose
Maintenance dose: 0.25 mg subcutaneously every other day

Schedule for dose titration:
Weeks 1 and 2: 0.0625 mg subcutaneously every other day (25% of recommended dose)
Weeks 3 and 4: 0.125 mg subcutaneously every other day (50% of recommended dose)
Weeks 5 and 6: 0.1875 mg subcutaneously every other day (75% of recommended dose)
Week 7 and beyond: 0.25 mg subcutaneously every other day (100% of recommended dose)

Usual Adult Dose for Colorectal Cancer

(Not approved by FDA)

Phase II trials - advanced colorectal carcinoma (n=81)
9 million international units subcutaneously on days 1, 3, and 5, thereafter 3 times a week (in combination with fluorouracil)

Usual Pediatric Dose for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

(Not approved by FDA)

Case (n=1)
1.5 million international units subcutaneously twice a week for 1 week, then 3 million international units 3 times a week

Usual Pediatric Dose for Multiple Sclerosis

(Not approved by FDA)

Study (n=1)
Greater than 8.5 years: 8 million international units (0.25 mg) subcutaneously every other day

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

If serum transaminase levels significantly increase or are associated with clinical symptoms (e.g., jaundice) during treatment: Consider discontinuing interferon beta-1b.

Precautions

Consult WARNINGS section for dosing related precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Pretreatment with analgesics and/or antipyretics on treatment days may ameliorate flu-like symptoms. Also, a study (n=71) suggests that the use oral low-dose steroids at the start of therapy lessens the incidence and severity of flu-like symptoms for the first 2 weeks of treatment.
-The first injection of interferon beta-1b should be done under supervision of a qualified healthcare professional. Train patients or caregivers who will administer the drug in the proper technique and assess their ability to inject subcutaneously to ensure proper administration of interferon beta-1b.
-Visually inspect reconstituted solution before use; discard if it contains particulate matter or is discolored.
-Keeping the syringe and vial adapter in place, turn the assembly over so that the vial is on top. Withdraw the proper dose. Remove the vial from the vial adapter before injecting interferon beta-1b.
-Use safe disposal procedures for needles and syringes; do not reuse needles or syringes.
-Rotate subcutaneous injection sites to reduce the risk of severe injection site reactions, including necrosis or localized infection.
-A missed dose of interferon beta-1b should be taken as soon as the patient remembers or is able to take it. Interferon beta-1b should not be taken on 2 consecutive days. The next injection should be taken about 48 hours after that dose. Patients taking more than the prescribed dose, or taking it on 2 consecutive days, should be advised to contact their healthcare provider at once.

Storage requirements:
-Prior to reconstitution: Store vials at room temperature.
-After reconstitution: If not used immediately, refrigerate the reconstituted solution and use within 3 hours. Do not freeze.

Reconstitution/preparation techniques:
(a) Prior to reconstitution, verify that the vial containing lyophilized interferon beta-1b is not cracked or damaged. Do not use cracked or damaged vials.
(b) To reconstitute lyophilized interferon beta-1b, attach the prefilled syringe containing the diluent (Sodium Chloride, 0.54% Solution) to the interferon beta-1b vial using the vial adapter.
(c) Slowly inject 1.2 mL of diluent into the interferon beta-1b vial.
(d) Gently swirl the vial to completely dissolve the lyophilized powder; do not shake. Foaming may occur during reconstitution or if the vial is swirled or shaken too vigorously. If foaming occurs, let the vial sit undisturbed until the foam settles.
(e) 1 mL of reconstituted solution contains 0.25 mg of interferon beta-1b.

Monitoring:
-Cardiovascular: Worsening cardiac symptoms in patients with congestive heart failure (at the start of and during therapy).
-Hematologic: Complete blood and differential white blood cell counts and platelet counts at regular intervals (1, 3, and 6 months) following start of therapy, then periodically thereafter if no clinical symptoms (more intensive monitoring in patients with myelosuppression).
-Hepatic: Liver function tests at regular intervals (1, 3, and 6 months) following start of therapy, then periodically thereafter if no clinical symptoms; signs and symptoms of hepatic injury.
-Metabolic: Blood chemistries at regular intervals (1, 3, and 6 months) following start of therapy, then periodically thereafter if no clinical symptoms.

Hide
(web1)